The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwHRMM 2024 | The role of imaging in myeloma diagnosis and in assessing treatment response
Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, outlines what physicians should know about imaging in multiple myeloma (MM), explaining that while baseline imaging maps and stages the disease, it holds less prognostic relevance than genomic factors. However, imaging becomes essential in high-risk patients, such as those with high lactate dehydrogenase (LDH) levels or previous plasmacytomas, to accurately evaluate the response to therapy. This discussion took place at the 1st International Workshop on High-Risk Multiple Myeloma (iwHRMM 2024), held in Charleston, SC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
